 Graves Ophthalmopathy
"Graves Ophthalmopathy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An autoimmune disorder of the EYE, occurring in patients with Graves disease. Subtypes include congestive (inflammation of the orbital connective tissue), myopathic (swelling and dysfunction of the extraocular muscles), and mixed congestive-myopathic ophthalmopathy.
| Descriptor ID |
D049970
|
| MeSH Number(s) |
C11.270.842 C11.675.349.500.500 C19.874.283.605.500 C19.874.397.370.500 C20.111.555.500
|
| Concept/Terms |
Graves Ophthalmopathy- Graves Ophthalmopathy
- Ophthalmopathy, Graves
- Ophthalmopathies, Thyroid-Associated
- Ophthalmopathies, Thyroid Associated
- Thyroid-Associated Ophthalmopathies
- Thyroid Associated Ophthalmopathies
- Thyroid-Associated Ophthalmopathy
- Thyroid Associated Ophthalmopathy
- Dysthyroid Ophthalmopathy
- Dysthyroid Ophthalmopathies
- Ophthalmopathies, Dysthyroid
- Ophthalmopathy, Dysthyroid
- Ophthalmopathy, Thyroid-Associated
- Ophthalmopathy, Thyroid Associated
Myopathic Ophthalmopathy- Myopathic Ophthalmopathy
- Myopathic Ophthalmopathies
- Ophthalmopathies, Myopathic
- Ophthalmopathy, Myopathic
Congestive Ophthalmopathy- Congestive Ophthalmopathy
- Congestive Ophthalmopathies
- Ophthalmopathies, Congestive
- Ophthalmopathy, Congestive
- Ophthalmopathy, Infiltrative
- Infiltrative Ophthalmopathies
- Infiltrative Ophthalmopathy
- Ophthalmopathies, Infiltrative
- Edematous Ophthalmopathy
- Edematous Ophthalmopathies
- Ophthalmopathies, Edematous
- Ophthalmopathy, Edematous
|
Below are MeSH descriptors whose meaning is more general than "Graves Ophthalmopathy".
Below are MeSH descriptors whose meaning is more specific than "Graves Ophthalmopathy".
This graph shows the total number of publications written about "Graves Ophthalmopathy" by people in this website by year, and whether "Graves Ophthalmopathy" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 | | 2014 | 2 | 0 | 2 | | 2015 | 1 | 0 | 1 | | 2016 | 1 | 0 | 1 | | 2017 | 1 | 0 | 1 | | 2021 | 1 | 0 | 1 | | 2022 | 3 | 0 | 3 | | 2023 | 4 | 0 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Graves Ophthalmopathy" by people in Profiles.
-
Douglas RS, Couch S, Wester ST, Fowler BT, Liu CY, Subramanian PS, Tang R, Nguyen QT, Maamari RN, Ugradar S, Hsu K, Karon M, Stan MN. Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity. J Clin Endocrinol Metab. 2023 Dec 21; 109(1):25-35.
-
Kahaly GJ, Dolman PJ, Wolf J, Giers BC, Elflein HM, Jain AP, Srinivasan A, Hadjiiski L, Jordan D, Bradley EA, Stan MN, Eckstein A, Pitz S, Vorl?nder C, Wester ST, Nguyen J, Tucker N, Sales-Sanz M, Feldon SE, Nelson CC, Hardy I, Abia-Serrano M, Tedeschi P, Janes JM, Xu J, Vue P, Macias WL, Douglas RS. Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease. J Clin Endocrinol Metab. 2023 Nov 17; 108(12):3122-3134.
-
Abboud JJ, Badawe H, Nguyen J, Khraiche ML, Sivak-Callcott JA. Kinematics of the Upper Eyelid and the Globe During Downward Excursion With Comparative Analysis in Patients With Thyroid Eye Disease. Ophthalmic Plast Reconstr Surg. 2024 Mar-Apr 01; 40(2):167-173.
-
Subramanian PS, Cho RI, Kahana A. Efficacy of teprotumumab therapy in patients with long-duration thyroid eye disease. Curr Opin Ophthalmol. 2023 Nov 01; 34(6):487-492.
-
Ting MA, Ozzello DJ, Topilow NJ, Yoon JS, Liu CY, Korn BS, Kikkawa DO. Differential effects of teprotumumab treatment based on fat-to-muscle ratio in patients with thyroid eye disease. Orbit. 2023 Aug; 42(4):418-425.
-
Douglas RS, Dailey R, Subramanian PS, Barbesino G, Ugradar S, Batten R, Qadeer RA, Cameron C. Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison. JAMA Ophthalmol. 2022 04 01; 140(4):328-335.
-
Douglas RS, Kossler AL, Abrams J, Brice?o CA, Gay D, Harrison A, Lee M, Nguyen J, Joseph SS, Schlachter D, Tan J, Lynch J, Oliver L, Perry R, Ugradar S. Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach. J Neuroophthalmol. 2022 09 01; 42(3):334-339.
-
Ozzello DJ, Dallalzadeh LO, Liu CY. Teprotumumab for chronic thyroid eye disease. Orbit. 2022 Oct; 41(5):539-546.
-
Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Salvi M, Goldberg RA, Gigantelli JW, Couch SM, Shriver EM, Hayek BR, Hink EM, Woodward RM, Gabriel K, Magni G, Douglas RS. Teprotumumab for Thyroid-Associated Ophthalmopathy. N Engl J Med. 2017 05 04; 376(18):1748-1761.
-
Singh J, Choi CS, Bahl R, Archer SM. Partial tendon recession for small-angle vertical strabismus. J AAPOS. 2016 10; 20(5):392-395.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|